{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:28:18Z","timestamp":1761874098216,"version":"build-2065373602"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T00:00:00Z","timestamp":1477526400000},"content-version":"vor","delay-in-days":1395,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA108775","CA21765"],"award-info":[{"award-number":["CA108775","CA21765"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007737","name":"St. Jude Children's Research Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000953","name":"Alliance for Cancer Gene Therapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000953","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1P01CA163205-01A1"],"award-info":[{"award-number":["1P01CA163205-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2013]]},"DOI":"10.1038\/mtna.2013.38","type":"journal-article","created":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T11:47:51Z","timestamp":1375789671000},"page":"e113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs"],"prefix":"10.1016","volume":"2","author":[{"given":"Kazue","family":"Kasai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitch","family":"Phelps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip M","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William B","family":"Goins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soledad A","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E Antonio","family":"Chiocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/mtna.2013.38_bib1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1038\/mtna.2013.38_bib2","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/jnci\/djr077","article-title":"Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system","volume":"103","author":"Kohler","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/mtna.2013.38_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2174\/157488710790820544","article-title":"Current therapeutic paradigms in glioblastoma","volume":"5","author":"Quick","year":"2010","journal-title":"Rev Recent Clin Trials"},{"key":"10.1038\/mtna.2013.38_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1215\/15228517-2006-025","article-title":"The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme","volume":"9","author":"Ballman","year":"2007","journal-title":"Neuro-oncology"},{"key":"10.1038\/mtna.2013.38_bib5","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1101\/gad.1596707","article-title":"Malignant astrocytic glioma: genetics, biology, and paths to treatment","volume":"21","author":"Furnari","year":"2007","journal-title":"Genes Dev"},{"key":"10.1038\/mtna.2013.38_bib6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant gliomas in adults","volume":"359","author":"Wen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1038\/mtna.2013.38_bib7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrn3060","article-title":"The neurobiology of gliomas: from cell biology to the development of therapeutic approaches","volume":"12","author":"Westphal","year":"2011","journal-title":"Nat Rev Neurosci"},{"key":"10.1038\/mtna.2013.38_bib8","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","author":"Cancer Genome Atlas Research Network","year":"2008","journal-title":"Nature"},{"key":"10.1038\/mtna.2013.38_bib9","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nrc948","article-title":"Oncolytic viruses","volume":"2","author":"Chiocca","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/mtna.2013.38_bib10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/PPO.0b013e3182458b13","article-title":"Gene and viral therapy for glioblastoma: a review of clinical trials and future directions","volume":"18","author":"Mohyeldin","year":"2012","journal-title":"Cancer J"},{"key":"10.1038\/mtna.2013.38_bib11","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/sj.cgt.7700946","article-title":"Herpes simplex virus 1 (HSV-1) for cancer treatment","volume":"13","author":"Shen","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mtna.2013.38_bib12","first-page":"103","article-title":"Herpesvirus vectors for therapy of brain tumors","volume":"4","author":"Cassady","year":"2010","journal-title":"Open Virol J"},{"key":"10.1038\/mtna.2013.38_bib13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1586\/ern.09.9","article-title":"Design and application of oncolytic HSV vectors for glioblastoma therapy","volume":"9","author":"Grandi","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"10.1038\/mtna.2013.38_bib14","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.2741\/2823","article-title":"Oncolytic virus therapy using genetically engineered herpes simplex viruses","volume":"13","author":"Todo","year":"2008","journal-title":"Front Biosci"},{"key":"10.1038\/mtna.2013.38_bib15","first-page":"123","article-title":"HSV Recombinant Vectors for Gene Therapy","volume":"4","author":"Manservigi","year":"2010","journal-title":"Open Virol J"},{"key":"10.1038\/mtna.2013.38_bib16","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ymthe.2005.07.357","article-title":"Gene therapy for malignant glioma: current clinical status","volume":"12","author":"Pulkkanen","year":"2005","journal-title":"Mol Ther"},{"key":"10.1038\/mtna.2013.38_bib17","doi-asserted-by":"crossref","first-page":"6850","DOI":"10.1158\/0008-5472.CAN-05-0154","article-title":"Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan","volume":"65","author":"Tyminski","year":"2005","journal-title":"Cancer Res"},{"key":"10.1038\/mtna.2013.38_bib18","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1038\/onc.2008.53","article-title":"Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16","volume":"27","author":"Aghi","year":"2008","journal-title":"Oncogene"},{"key":"10.1038\/mtna.2013.38_bib19","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm0995-938","article-title":"Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas","volume":"1","author":"Mineta","year":"1995","journal-title":"Nat Med"},{"key":"10.1038\/mtna.2013.38_bib20","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.gt.3301205","article-title":"Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial","volume":"7","author":"Markert","year":"2000","journal-title":"Gene Ther"},{"key":"10.1038\/mtna.2013.38_bib21","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1089\/hum.1994.5.8-969","article-title":"Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene","volume":"5","author":"Wei","year":"1994","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtna.2013.38_bib22","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1021\/jm9001296","article-title":"Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) toxicity","volume":"52","author":"Hicks","year":"2009","journal-title":"J Med Chem"},{"key":"10.1038\/mtna.2013.38_bib23","first-page":"20","article-title":"Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11","volume":"58","author":"Danks","year":"1998","journal-title":"Cancer Res"},{"key":"10.1038\/mtna.2013.38_bib24","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00281-011-0245-0","article-title":"Immunomodulatory effects of cyclophosphamide and implementations for vaccine design","volume":"33","author":"Sistigu","year":"2011","journal-title":"Semin Immunopathol"},{"key":"10.1038\/mtna.2013.38_bib25","first-page":"2344","article-title":"Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation","volume":"49","author":"Clarke","year":"1989","journal-title":"Cancer Res"},{"key":"10.1038\/mtna.2013.38_bib26","first-page":"975","article-title":"Comparative effects of cyclophosphamide, isophosphamide, 4-methylcyclophosphamide, and phosphoramide mustard on murine hematopoietic and immunocompetent cells","volume":"62","author":"Sensenbrenner","year":"1979","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/mtna.2013.38_bib27","doi-asserted-by":"crossref","first-page":"702839","DOI":"10.1155\/2012\/702839","article-title":"Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer cells","volume":"2012","author":"Alvarez-Breckenridge","year":"2012","journal-title":"Adv Virol"},{"key":"10.1038\/mtna.2013.38_bib28","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/jnci\/djm229","article-title":"Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy","volume":"99","author":"Kurozumi","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/mtna.2013.38_bib29","doi-asserted-by":"crossref","first-page":"9398","DOI":"10.1158\/0008-5472.CAN-07-1063","article-title":"Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses","volume":"67","author":"Fulci","year":"2007","journal-title":"Cancer Res"},{"key":"10.1038\/mtna.2013.38_bib30","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ymthe.2006.08.008","article-title":"Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging","volume":"14","author":"Lamfers","year":"2006","journal-title":"Mol Ther"},{"key":"10.1038\/mtna.2013.38_bib31","doi-asserted-by":"crossref","first-page":"11255","DOI":"10.1158\/0008-5472.CAN-05-2278","article-title":"Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus","volume":"65","author":"Kambara","year":"2005","journal-title":"Cancer Res"},{"key":"10.1038\/mtna.2013.38_bib32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1006\/mthe.2002.0547","article-title":"The complement response against an oncolytic virus is species-specific in its activation pathways","volume":"5","author":"Wakimoto","year":"2002","journal-title":"Mol Ther"},{"key":"10.1038\/mtna.2013.38_bib33","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/11320","article-title":"Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses","volume":"5","author":"Ikeda","year":"1999","journal-title":"Nat Med"},{"key":"10.1038\/mtna.2013.38_bib34","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/nm.3013","article-title":"NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors","volume":"18","author":"Alvarez-Breckenridge","year":"2012","journal-title":"Nat Med"},{"key":"10.1038\/mtna.2013.38_bib35","doi-asserted-by":"crossref","first-page":"12873","DOI":"10.1073\/pnas.0605496103","article-title":"Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses","volume":"103","author":"Fulci","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mtna.2013.38_bib36","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1248\/bpb.17.662","article-title":"Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase","volume":"17","author":"Satoh","year":"1994","journal-title":"Biol Pharm Bull"},{"key":"10.1038\/mtna.2013.38_bib37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1215\/15228517-2008-075","article-title":"Experience with irinotecan for the treatment of malignant glioma","volume":"11","author":"Vredenburgh","year":"2009","journal-title":"Neuro-oncology"},{"key":"10.1038\/mtna.2013.38_bib38","first-page":"3861","article-title":"Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine\/rat cytochrome P450 2B1 and ganciclovir\/herpes simplex virus thymidine kinase gene therapies","volume":"59","author":"Aghi","year":"1999","journal-title":"Cancer Res"},{"key":"10.1038\/mtna.2013.38_bib39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/bms.1200020109","article-title":"Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite","volume":"2","author":"Struck","year":"1975","journal-title":"Biomed Mass Spectrom"},{"key":"10.1038\/mtna.2013.38_bib40","first-page":"89","article-title":"Pharmacology of cyclophosphamide and metabolites","volume":"65","author":"Colvin","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"10.1038\/mtna.2013.38_bib41","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2165\/00003088-200038040-00001","article-title":"Metabolism and pharmacokinetics of oxazaphosphorines","volume":"38","author":"Boddy","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1038\/mtna.2013.38_bib42","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0090-9556(24)15302-0","article-title":"Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles","volume":"27","author":"Roy","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1038\/mtna.2013.38_bib43","first-page":"3627","article-title":"Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme","volume":"58","author":"Potter","year":"1998","journal-title":"Cancer Res"},{"key":"10.1038\/mtna.2013.38_bib44","first-page":"1171","article-title":"Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide\/cytochrome P450 2B1 cancer gene therapy paradigm","volume":"1","author":"Wei","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mtna.2013.38_bib45","first-page":"864","article-title":"Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector","volume":"61","author":"Ichikawa","year":"2001","journal-title":"Cancer Res"},{"key":"10.1038\/mtna.2013.38_bib46","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/sj.gt.3302143","article-title":"Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis","volume":"11","author":"Wakimoto","year":"2004","journal-title":"Gene Ther"},{"key":"10.1038\/mtna.2013.38_bib47","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nbt0598-444","article-title":"An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy","volume":"16","author":"Chase","year":"1998","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mtna.2013.38_bib48","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.1128\/jvi.71.7.5560-5569.1997","article-title":"The range and distribution of murine central nervous system cells infected with the \u03b3(1)34.5- mutant of herpes simplex virus 1","volume":"71","author":"Markovitz","year":"1997","journal-title":"J Virol"},{"key":"10.1038\/mtna.2013.38_bib49","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/sj.gt.3300639","article-title":"Potential and limitations of a gamma 34.5 mutant of herpes simplex 1 as a gene therapy vector in the CNS","volume":"5","author":"McMenamin","year":"1998","journal-title":"Gene Ther"},{"key":"10.1038\/mtna.2013.38_bib50","first-page":"739","article-title":"Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants","volume":"2","author":"Chiocca","year":"1990","journal-title":"New Biol"},{"key":"10.1038\/mtna.2013.38_bib51","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1128\/jvi.69.3.1389-1399.1995","article-title":"Quantification of transcripts from the ICP4 and thymidine kinase genes in mouse ganglia latently infected with herpes simplex virus","volume":"69","author":"Kramer","year":"1995","journal-title":"J Virol"},{"key":"10.1038\/mtna.2013.38_bib52","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1128\/jvi.74.10.4765-4775.2000","article-title":"Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant","volume":"74","author":"Ikeda","year":"2000","journal-title":"J Virol"},{"key":"10.1038\/mtna.2013.38_bib53","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1089\/hum.1997.8.17-2057","article-title":"Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy","volume":"8","author":"Kramm","year":"1997","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mtna.2013.38_bib54","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/sj.gt.3302717","article-title":"Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models","volume":"13","author":"Terada","year":"2006","journal-title":"Gene Ther"}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216225311630172X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216225311630172X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:22:51Z","timestamp":1761873771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S216225311630172X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":54,"alternative-id":["S216225311630172X"],"URL":"https:\/\/doi.org\/10.1038\/mtna.2013.38","relation":{},"ISSN":["2162-2531"],"issn-type":[{"type":"print","value":"2162-2531"}],"subject":[],"published":{"date-parts":[[2013]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/mtna.2013.38","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Society of Gene & Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"e113"}}